<DOC>
	<DOCNO>NCT00798265</DOCNO>
	<brief_summary>Background : - Human papilloma virus ( HPV ) common sexually transmitted disease . There 100 different HPV type , male female get HPV infection . Most people symptoms become infected able get rid infection . However , still become re-infected different HPV type , people HPV infection persists . - Persistent HPV infection associate development precancerous lesion cancer . HPV type classify either high risk low risk base whether persistence lead cancer . - Patients suppress immune system high risk HPV-related complication . They likely contract multiple HPV type persistent infection lead precancerous lesion cancer , difficult treat often recur . - A recently approve vaccine HPV induce immunity HPV 6 , 11 , 16 , 18 . It show highly effective prevent infection HPV type , approve use females 9 26 year age . However , much less known vaccine ability induce immunity male individual suppress immune system . Objectives : - To investigate whether HPV vaccine safe give able induce immunity female male adolescent young adult HIV infection compare healthy , HIV-negative person age . Eligibility : - Males female , 12 26 year age , divide three group : ( 1 ) Healthy HIV-negative , ( 2 ) HIV-positive antiretroviral therapy , ( 3 ) HIV-positive antiretroviral therapy . Design : - Before begin vaccination , participant complete physical examination blood drawn routine blood test , special test immune system , antibody test , HIV test . - HPV vaccine give injection muscle 0 , 2 , 6 month , accord standard vaccination schedule . - Patients HIV infection monitor week follow first injection test level HIV blood 3 day 5 day first injection . - Participants also ask fill 10- 15-minute Web-based survey awareness , health behavior , personal choice relate risk factor HIV , HPV , sexually transmit disease . Participants require fill survey receive vaccine . - The total duration study 4 year . During first year study , participant return six additional 1-day visit month 1 , 2 , 3 , 6 , 7 , 12 . Participants return 1-day visit every 6 month remain 3 year .</brief_summary>
	<brief_title>A Phase I Study Quadrivalent Human Papilloma Virus ( HPV ) ( Types 6 , 11 , 16 , 18 ) Recombinant Vaccine HIV-Infected HIV-Negative Pre-Adolescents , Adolescents , Young Adults</brief_title>
	<detailed_description>Background : Human papilloma virus ( HPV ) one common sexually transmitted disease significant cause cutaneous genital wart anogenital cancer . Infection high-risk , oncogenic HPV type , commonly type 16 18 , associate low high-grade cervical cellular abnormality precursor invasive cervical cancer , well vulvar anal cancer , HPV type 6 11 associate genital wart . Persistence HPV infection common individual risk chronic immunosuppression HIV-infected individual high prevalence HPV infection HPV-associated anogential disease compare age-matched HIV-negative control . Study Objectives : To assess safety immunogenicity quadrivalent human papillomavirus ( type 6 , 11 , 16 , 18 ) recombinant vaccine HIV-infected preadolescents , adolescent young adult 12-26 year age . To determine whether difference HPV vaccine immunogenicity HIV-infected HIV negative age-matched control . To determine whether difference HPV vaccine immunogenicity HIV-infected patient receive highly active antiretroviral therapy ( HAART ) receive HAART similar CD4 viral load parameter entry . To determine whether HPV vaccination alters HIV-1 RNA level . To investigate impact CD4 count HIV-1 RNA level HPV vaccine immunogenicity . To characterize HPV DNA positivity study cohort population oral/buccal anogenital sample baseline . To characterize HPV HIV knowledge risk sexual behavior study cohort population . Eligibility : Individual Cohorts Cohort 1 : HIV-positive , CD4 cell count great equal 350 cells/mm3 , HIV-1 RNA level RT PCR less equal 20,000 copies/ml , stable HAART regimen great equal 6 month . Cohort 2 : HIV-infected , CD4 cell count great equal 500 cells/mm3 , HIV-1 RNA level RT PCR less equal 20,000 copies/ml , antiretroviral treatment . Cohort 3 : healthy , HIV-negative control All Cohorts Females males age 12 26 year Patients must hemoglobin great equal 10.0 gm/dL , neutrophil count ( ANC ) great equal 1500/mm3 , platelet count great equal 75,000/mm3 PT PTT less equal 1.5x ULN ( exception patient know clot disorder lupus anticoagulant ) ; SGPT/SGOT &lt; 2/5x ULN , total bilirubin less equal 1.5x ULN unless attributable protease inhibitor therapy . Patients must test negative hepatitis B virus hepatitis C virus , unless result consistent prior vaccination prior infection full recovery . No use investigational agent within 4 week study enrollment use immunosuppressive immunomodulating agent within 8 week study entry . Study Design : This non-randomized , prospective , phase I study quadrivalent human papillomavirus ( type 6 , 11 , 16 , 18 ) recombinant vaccine . The study include 3 cohort pre-adolescents , adolescent young adult 12-26 year age outline Eligibility Criteria . Each cohort enroll 35 patient . All study subject receive three dos HPV vaccine 0 , 2 6 month administer IM . Study participant monitor month 0 , 1 , 2 , 3 , 6 , 7 , 12 ( +/- 2 week visit , every 6 month ( +/- 30 day ) thereafter 48 month total .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<criteria>ELIGIBILITY CRITERIA : Cohort 1 Inclusion Exclusion Eligibility Criteria : INCLUSION CRITERIA : 2.1.1.1 Age 12 26 year 2.1.1.2 Females male 2.1.1.3 HIVpositive 2.1.1.4 CD4 cell count HIV1 RNA level parameter CD4 cell count great equal 350 cells/mm ( 3 ) HIV1 RNA level RT PCR less equal 20,000 copies/ml 2.1.1.5 On stable HAART regimen great equal 6 month CD4 viral load parameter outline 2.1.1.4 2.1.1.6 Patients great equal 18 year willing provide inform consent parent/guardian willing provide inform consent minor child le 18 year age . 2.1.1.7 Informed assent patient 1217 year age ( Optional discretion Principal Investigator Parent/Guardian base maturity level minor ) 2.1.1.8 Willing use acceptable form contraception , applicable , abstinence prevent pregnancy . EXCLUSION CRITERIA : 2.1.1.9 Any follow hematologic abnormality Hemoglobin le 10.0 g/dL Neutrophil count le 1500/mm ( 3 ) Platelet count le 75,000/mm ( 3 ) PT PTT great equal 1.5 time ULN ( exception patient know clot disorder know lupus anticoagulant ) . 2.1.1.10 Any follow hepatic abnormality ALT/SGPT and/or AST/SGOT great 2.5 time ULN Total bilirubin great 1.5 time ULN unless attributable protease inhibitor therapy . 2.1.1.11 Positive test ( antibody and/or antigen ) hepatitis B hepatitis C virus , unless result consistent prior vaccination prior infection full recovery . 2.1.1.12 Acute infection require therapy time enrollment . Participants may eligible study stable appropriate antiinfective therapy . 2.1.1.13 Chemotherapy active cancer . 2.1.1.14 Documented history nonadherence antiretroviral treatment regimen within 12 month study entry . 2.1.1.15 Pregnancy breastfeeding . 2.1.1.16 Use immunosuppressive immunomodulating agent within 8 week study enrollment . Note : patient receive oral corticosteroid management asthma contact hypersensitivity less equal 14 day duration allow enroll long great equal 30 day since oral corticosteroid administration . 2.1.1.17 Known immediate hypersensitivity yeast vaccine component . 2.1.1.18 Use investigational agent within 4 week prior study enrollment . 2.1.1.19 Active external genital wart require treatment CIN2/3 2.1.1.20 Any clinically significant disease ( HIV infection ) finding study screening , opinion Principal Investigator Lead Associate Investigator , may interfere study . Cohort 2 Inclusion Exclusion Eligibility Criteria : Inclusion Criteria 2.1.2.1 Age 12 26 year 2.1.2.2 Females male 2.1.2.3 HIVpositive 2.1.2.4 CD4 cell count HIV1 RNA level parameter CD4 cell count great equal 500 cells/mm ( 3 ) HIV1 RNA level RT PCR less equal 20,000 copies/ml . 2.1.2.5 Not receive antiretroviral treatment CD4 viral load parameter outline 2.1.2.4 . 2.1.2.6 Patients great equal 18 year willing provide inform consent parent/guardian willing provide inform consent minor child le 18 year age . 2.1.2.7 Informed assent patient 1217 year age ( Optional discretion Principal Investigator Parent/Guardian base maturity level minor ) 2.1.2.8 Willing use acceptable form contraception , applicable , abstinence prevent pregnancy . EXCLUSION CRITERIA : 2.1.2.9 Any follow hematologic abnormality : Hemoglobin le 10.0 g/dL Neutrophil count le 1500/mm ( 3 ) Platelet count le 75,000/mm ( 3 ) PT PTT great equal 1.5 time ULN ( exception patient know clot disorder know lupus anticoagulant ) . 2.1.2.10 Any follow hepatic abnormality ALT/SGPT and/or AST/SGOT great 2.5 time ULN Total bilirubin great 1.5 time ULN unless attributable protease inhibitor therapy . 2.1.2.11 Positive test ( antibody and/or antigen ) hepatitis B hepatitis C virus , unless result consistent prior vaccination prior infection full recovery . 2.1.2.12 Acute infection require therapy time enrollment . Participants may eligible study stable appropriate antiinfective therapy . 2.1.2.13 Chemotherapy active cancer . 2.1.2.14 Pregnancy breastfeeding . 2.1.2.15 Use immunosuppressive immunomodulating agent within 8 week prior study enrollment . Note : patient receive oral corticosteroid management asthma contact hypersensitivity less equal 14 day duration allow enroll long great equal 30 day since oral corticosteroid administration . 2.1.2.16 Known immediate hypersensitivity yeast vaccine component . 2.1.2.17 Use investigational agent within 4 week prior study enrollment . 2.1.2.18 Active external genital wart require treatment CIN2/3 2.1.2.19 Any clinically significant disease ( HIV infection ) finding study screening , opinion Principal Investigator Lead Associate Investigator may interfere study . Cohort 3 Inclusion Exclusion Eligibility Criteria : INCLUSION CRITERIA : 2.1.3.1 Age 12 26 year 2.1.3.2 Females male 2.1.3.3 HIVnegative 2.1.3.4 Patients great equal 18 year willing provide inform consent parent/guardian willing provide inform consent minor child le 18 year age . 2.1.3.5 Informed assent patient 1217 year age ( Optional discretion Principal Investigator Parent/Guardian base maturity level minor ) 2.1.3.6 Willing use acceptable form contraception , applicable , abstinence prevent pregnancy . EXCLUSION CRITERIA : 2.1.3.7 Any follow hematologic abnormality : Hemoglobin le 10.0 g/dL Neutrophil count le 1500/mm ( 3 ) Platelet count le 75,000/mm ( 3 ) PT PTT great equal 1.5 time ULN ( exception patient know clot disorder know lupus anticoagulant ) . 2.1.3.8 Any follow hepatic abnormality ALT/SGPT and/or AST/SGOT great 2.5 time ULN Total Bilirubin great 1.5 time ULN unless attributable protease inhibitor therapy . 2.1.3.9 Positive test ( antibody and/or antigen ) HIV , hepatitis B hepatitis C virus , unless result consistent prior vaccination prior infection full recovery . 2.1.3.10 Acute infection require therapy time enrollment . Participants may eligible study stable appropriate antiinfective therapy . 2.1.3.11 Chemotherapy active cancer . 2.1.3.12 Pregnancy breastfeed 2.1.3.13 Use immunosuppressive immunomodulating agent within 8 week prior study enrollment . Note : patient receive oral corticosteroid management asthma contact hypersensitivity less equal 14 day duration allow enroll long great equal 30 day since oral corticosteroid administration . 2.1.3.14 Known immediate hypersensitivity yeast vaccine component . 2.1.3.15 Use investigational agent within 4 week prior study enrollment . 2.1.3.16 Active external genital wart require treatment CIN2/3 2.1.3.17 Any clinically significant disease finding study screening , opinion Principal Investigator Lead Associate Investigator may interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>October 27, 2016</verification_date>
	<keyword>HPV Vaccination</keyword>
	<keyword>HPV Immunogenicity</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>HIV Negative</keyword>
	<keyword>Adolescents Young Adults</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
	<keyword>Adolescent</keyword>
</DOC>